What’s going on in the world of vasculitis…?
Rare Disease Day is marked every year on the last day of February. On this day, patients, families, healthcare professionals and organisations around the world come together to raise awareness about rare diseases and the people living with them.
A large European multicentre study involving 162 patients provides important new insights into interstitial lung disease (ILD) associated with ANCA antibodies. The findings highlight that lung fibrosis is a serious and often under-recognised complication within the ANCA disease spectrum. One of the key messages emerging from this study is that patients with ANCA-associated ILD should ideally be managed by a multidisciplinary team. Although kidney involvement was common, it did not independently predict mortality. This suggests that lung disease severity at baseline may be the main driver of long-term outcomes in this population.
The current review is a so called Article 20 non-pharmacovigilance procedure. This type of procedure is used when questions arise about the scientific basis or robustness of the data that supported the original approval of a medicine.
It is not started because of new safety problems or concerns about side effects for patients.
In November, patients, caregivers, clinicians and researchers from more than a dozen European countries met in Prague for the 2025 European Vasculitis Patient Summit.
A landmark review in Nature Reviews Rheumatology calls for a new, integrated approach to ANCA-associated vasculitis.When diagnosis, classification, biomarkers and patient experience come together, care becomes truly personal — and outcomes improve.
Melbourne Februari 21-25 2026
The 22nd edition of this international workshop on vasculitis will take place from February 21 to 25, 2026, in Melbourne, Australia. Organized by the Australian and New Zealand Vasculitis Society (ANZVASC).